# US 2026/0028309 A1 · Polymorphic forms of rad1901-2hcl

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0028309 A1
- Document ID: US20260028309A1
- Status: Published application
- Kind: A1
- Application number: 19/283,114
- Filed: 2025-07-28
- Published: 2026-01-29
- Earliest claimed: 2017-01-05
- Assignees: Radius Pharmaceuticals, Inc.
- Applicants: Radius Pharmaceuticals, Inc.
- Inventors: Michael Paul CRUSKIE, JR.; Joshua Kyle Bolger; Jonathan Blake McKenzie; Pratik Sheth; Richard Edwards; Alex Eberlin; Michael Markey
- Web page: https://patentgrep.com/patent/US20260028309A1

## CPC

- C07C 217/84: the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
- A61P 35/00: Antineoplastic agents
- C07C 213/10: Separation; Purification; Stabilisation; Use of additives
- C07B 2200/07: Optical isomers
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07C 2602/10: the other ring being six-membered, e.g. tetraline
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.

## Claims

### Claim 1

A solid form of RAD1901-2HCl,
characterized as Form 3, having an X-Ray powder diffraction pattern comprising a peak, in terms of 2-theta, at 5.8 degrees 2θ±0.2 degree 2θ at relative humidity 95%.

### Claim 2 (depends on 1)

The solid Form 3 of RAD1901-2HCl according to claim 1, having an X-ray powder diffraction pattern further comprising a peak, in terms of 2-theta, at 21.3 degrees 2θ±0.2 degree 2θ, at relative humidity 92%.

### Claim 3 (depends on 2)

The solid Form 3 of RAD1901-2HCl according to claim 2, having an X-ray powder diffraction pattern further comprising a peak, in terms of 2-theta, at 24.8 degrees 2θ±0.2 degree 2θ, at relative humidity 92%.

### Claim 4 (depends on 3)

The solid Form 3 of RAD1901-2HCl according to claim 3, having an X-ray powder diffraction pattern further comprising a peak, in terms of 2-theta, at 23.3 degrees 2θ±0.2 degree 2θ, at relative humidity 92%.

### Claim 5 (depends on 4)

The solid Form 3 of RAD1901-2HCl according to claim 4, having an X-ray powder diffraction pattern further comprising a peak, in terms of 2-theta, at 12.1 degrees 2θ±0.2 degree 2θ, at relative humidity 92%.

### Claim 6 (depends on 5)

The solid Form 3 of RAD1901-2HCl according to claim 5, having an X-ray powder diffraction pattern further comprising a peak, in terms of 2-theta, at 9.5 degrees 2θ±0.2 degree 2θ.

### Claim 7 (depends on 1)

The solid Form 3 of RAD1901-2HCl according to claim 1, having an X-ray powder diffraction pattern substantially as shown in FIG. 5I at about relative humidity 92%.

### Claim 8 (depends on 1)

The solid Form 3 of RAD1901-2HCl according to claim 1, wherein the solid Form 3 is a hydrated form.

### Claim 9 (depends on 8)

The solid Form 3 of RAD1901-2HCl according to claim 8, wherein the solid Form 3 is a dihydrate.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The solid Form 3 of RAD1901-2HCl according to claim 1, or a pharmaceutical composition comprising the solid Form 3 of RAD1901-2HCl according to any one of claims 1-9 and one or more pharmaceutically acceptable excipients, for use in treating breast cancer or ovarian cancer.

### Claim 11 (depends on 10)

The solid Form 3 of RAD1901-2HCl, or the pharmaceutical composition for use according to claim 10, wherein said breast cancer or ovarian cancer is ER+.

### Claim 12 (depends on 11)

The solid Form 3 of RAD1901-2HCl, or the pharmaceutical composition for use according to claim 11, wherein the breast cancer or ovarian cancer is a resistant ER-driven cancer that progressed after endocrinological treatment, wherein the endocrinological treatment comprises administration of a drug selected from a Selective Estrogen Receptor Degrader (SERD), an aromatase inhibitor, a selective estrogen receptor modulator (SERM), a Human Epidermal Growth Factor Receptor 2 (Her2) inhibitor, a chemo therapeutic agent, an angiogenesis inhibitor, a cdk4/6 inhibitor, an m-TOR inhibitor, or rituximab.

### Claim 13 (depends on 12)

The solid Form 3 of RAD1901-2HCl, or the pharmaceutical composition for use according to claim 12, wherein
the SERD is selected from fulvestrant, 17β-[2-[4-[(diethylamino)methyl]-2-methoxyphenoxy]ethyl]-7α-methylestra-1,3,5(10)-trien-3-ol (TAS-108 or (SR16234), 11β-Fluoro-7α-(14,14,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17β-diol (ZK191703), (11β,17β)-11-[4-[[5-[(4,4,5,5,5-Pentafluoropentyl)sulfonyl]-pentyl]oxy]phenylestra-1,3,5,(10)-triene-3,17-diol (RU58668), Brilanestrant (GDC-0810 or (ARN-810), Etacstil (GW5638 or/DPC974), (S)-2-(4-(2-(3-(fluoromethyl)-azetidin-1-yl) ethoxy) phenyl)-3-(3-hydroxyphenyl)-4-methyl-2H-chromen-6-ol (SRN-927), and (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4- b]indol-1-yl)phenyl)acrylic acid (AZD9496);
the aromatase inhibitor is selected from anastrozole, exemestane, and letrozole;
the selective estrogen receptor modulator is selected from tamoxifen, raloxifene, lasofoxifene, and toremifene;
the Her2 inhibitor is selected from trastuzumab, lapatinib, ado-trastuzumab emtansine, and pertuzumab;
the chemo therapeutic agent is selected from abraxane, adriamycin, carboplatin, cytoxan, daunorubicin, doxil, ellence, fluorouracil, gemzar, helaven, lxempra, methotrexate, mitomycin, micoxantrone, navelbine, taxol, taxotere, thiotepa, vincristine, and xeloda; and
the angiogenesis inhibitor is bevacizumab.

### Claim 14 (depends on 10)

The solid Form 3 of RAD1901-2HCl, or the pharmaceutical composition for use according to claim 10, wherein the subject is further administered a cdk4/6 inhibitor and/or an m-TOR inhibitor.

### Claim 15 (depends on 14)

The solid Form 3 of RAD1901-2HCl, or the pharmaceutical composition for use according to claim 14, wherein the cdk4/6 inhibitor and/or m-TOR inhibitor is selected from palbociclib, ribociclib, abemaciclib, or everolimus, or a combination thereof.

### Claim 16 (depends on 11)

The solid Form 3 of RAD1901-2HCl, or the pharmaceutical composition for use according to claim 11, wherein the breast cancer or ovarian cancer is a resistant ER-driven cancer that progress after endocrinological treatment, wherein the breast cancer has one or more mutant ER binding domains comprising one or more mutations selected from the group consisting of Y537X1 wherein X1 is S, N, or C, D538G, L536X2 wherein X2 is R or Q, P535H, V534E, S463P, V3921, and E380Q, or a combination thereof.

### Claim 17 (depends on 10)

The solid Form 3 of RAD1901-2HCl, or the pharmaceutical composition for use according to claim 10, for use in treating breast cancer.

### Claim 18 (depends on 10)

The solid Form 3 of RAD1901-2HCl, or the pharmaceutical composition for use according to claim 10, for use in treating ovarian cancer.
